SLC5A2 and obstructive sleep apnea syndrome: On the one hand, large prospective randomized clinical trials are required to evaluate the effectiveness and safety of dapagliflozin in treating OSAHS, determine the additional health benefits that can be measured in comparison with other treatments, and determine whether other SGLT2 inhibitors, such as empagliflozin and canagliflozinare, can also improve the symptoms and prognosis of OSAHS patients.